Title

The rapidly evolving state of gene therapy

UMMS Affiliation

Horae Gene Therapy Center; Department of Pediatrics

Publication Date

2018-04-01

Document Type

Article

Disciplines

Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Genetic Phenomena | Genetics and Genomics | Therapeutics

Abstract

Gene therapy is emerging as a viable option for clinical therapy of monogenic disorders and other genetically defined diseases, with approved gene therapies available in Europe and newly approved gene therapies in the United States. In the past 10 years, gene therapy has moved from a distant possibility, even in the minds of much of the scientific community, to being widely realized as a valuable therapeutic tool with wide-ranging potential. The U.S. Food and Drug Administration has recently approved Luxturna (Spark Therapeutics Inc, Philadelphia, PA, USA), a recombinant adeno-associated virus (rAAV) 2 gene therapy for one type of Leber congenital amaurosis 2 ( 1 , 2 ). The European Medicines Agency (EMA) has approved 3 recombinant viral vector products: Glybera (UniQure, Amsterdam, The Netherlands), an rAAV vector for lipoprotein lipase deficiency; Strimvelis (Glaxo Smith-Kline, Brentford, United Kingdom), an ex vivo gammaretrovirus-based therapy for patients with adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID); and Kymriah (Novartis, Basel, Switzerland), an ex vivo lentivirus-based therapy to engineer autologous chimeric antigen-receptor T (CAR-T) cells targeting CD19-positive cells in acute lymphoblastic leukemia. These examples will be followed by the clinical approval of other gene therapy products as this field matures. In this review we provide an overview of the state of gene therapy by discussing where the field stands with respect to the different gene therapy vector platforms and the types of therapies that are available.

Keywords

AAV, approved clinical products, gammaretrovirus, gene editing, lentivirus, vector platforms

DOI of Published Version

10.1096/fj.201700982R

Source

FASEB J. 2018 Apr;32(4):1733-1740. doi: 10.1096/fj.201700982R. Link to article on publisher's site

Journal/Book/Conference Title

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Related Resources

Link to Article in PubMed

PubMed ID

31282760

Link to Full Text

Share

COinS